Renovaro restates multiple prior financials due to warrant accounting error

Lunai Bioworks Inc.

Audit Committee determined misstatements in Q3 FY2024, FY2024, and Q1 FY2025 filings over warrant exercises in March 2024.
Warrant exercises were not properly reflected as change in fair value of contingent consideration.
Company will amend the three filings as soon as practicable; prior reports should no longer be relied upon.
Restatement affects unaudited interim and audited annual consolidated financial statements.
Non-reliance extends to related press releases, shareholder communications, and investor presentations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.